4 Healthcare Stocks to Consider Right Now
As the stock market continues to evolve, healthcare stocks are emerging as attractive investment opportunities. Investors are increasingly looking at companies making significant strides in gene editing, artificial intelligence (AI) drug discovery, and obesity treatments. Below are four healthcare stocks that are currently worth considering for your investment portfolio.
Crispr Therapeutics (CRSP)
Crispr Therapeutics has been at the forefront of gene editing technology. Along with Vertex Pharmaceuticals (VRTX), they have developed Casgevy, the first gene-editing treatment approved for sickle cell disease and beta-thalassemia, both inherited blood disorders. In the second quarter of 2025, Vertex reported $30 million in sales for Casgevy, indicating that the product is gaining traction. With approximately 75 hospitals now equipped to administer the treatment, sales are expected to grow further in the upcoming years.
Intellia Therapeutics (NTLA)
Intellia Therapeutics is advancing its CRISPR gene-editing programs towards crucial milestones. They recently completed enrollment for a Phase 3 study targeting hereditary angioedema, with results anticipated in the first half of 2026. Furthermore, their treatment for ATTR amyloidosis shows promise, having demonstrated significant results in earlier trials. If successful, Intellia could be among the first to receive approval for an in vivo CRISPR therapy, potentially resetting how investors value gene-editing companies.
Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals operates a drug discovery platform powered by AI and has established partnerships with major pharma companies like Sanofi, Roche, and Bayer. Despite facing some market challenges, the company generated $19.2 million in revenue from collaborations in recent results. With several clinical trial updates expected in late 2025, positive outcomes could lead to a revaluation of the stock, unlocking significant upside potential.
Viking Therapeutics (VKTX)
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist in late-stage development for obesity. An injectable version of the treatment has shown promising results, achieving an average weight loss of up to 14.7% in mid-stage studies. However, the oral formulation faced challenges due to gastrointestinal side effects. With adjustments in dosage strategy, the company aims to improve tolerability and compete in a market projected to exceed $100 billion in annual sales.
Investors should weigh the potential of these companies as they navigate the complexities of the healthcare sector. With promising developments on the horizon, these stocks offer compelling valuations amidst a market often focused on AI names.
For those looking to stay updated on the latest trends and news in the stock market, you can visit Stock Market News. If you seek a reliable stock portfolio management service and retirement investment plans, check out Stock Portfolio Management. Our target is a 20% growth per year, helping you optimize your investment strategies.
